Replies to post #88957 on Biotech Values

[bladerunner1717]

re: TRBN

Are these numbers at all impressive?


Trubion presented the second course of re-treatment data from a Phase 2bstudy (15002) of TRU-015 for rheumatoid arthritis (RA) at the AmericanCollege of Rheumatology (ACR) Annual Meeting in Oct. 2009. Data continueto demonstrate that repeat administration of TRU-015 is well-toleratedand improves the signs and symptoms of RA as measured by the ACR rates.At 24 weeks after the second re-treatment course, subjects in the groupthat had received 800 mg of TRU-015 of the initial treatment achievedACR 20, 50 and 70 response rates of 72%, 39% and 21%, respectively.Results were similar to the response rates seen 24 weeks after the firstre-treatment of the same cohort as presented at the European LeagueAgainst Rheumatism (EULAR) Annual Meeting in June 2009 (70%, 40% and23%, respectively). Trubion has now administered more than 1,300 dosesof TRU-015 over a period of four and a half years.-- In Sept. 2009, patient enrollment was completed in the second Phase 2bstudy (2203) of TRU-015 for RA.


Bladerunner

[wallstarb]

I just post it - I seldom read it =)